TrialFinder  /  Landscape Report POSTERIOR FOSSA SYNDROME  ·  2026-07-18 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-07-18
VERSION  v1
SAMPLE  100 of 624 studies

posterior fossa syndrome

The posterior fossa syndrome clinical trial landscape includes 624 actively recruiting trials. Semantic expansion identified 622 additional trials beyond exact-match search, representing a 31100% discovery lift across related conditions and therapeutic approaches.

Recruiting
624
active trials
Expansion Lift
+31100%
622 additional trials
Top Sponsor
Children's National Research Institute
3 trials
Dominant Phase
NA
61 of 103 sampled
Pipeline Overview
Phase Distribution
NA
61
Early I
2
Phase 1
10
Phase 2
7
Phase 3
3
Phase 4
1
Other
19
Therapeutic Modalities
BEHAVIORAL
81
DRUG
33
DEVICE
26
OTHER
25
DIAGNOSTIC_TEST
16
PROCEDURE
9
RADIATION
4
BIOLOGICAL
3
Recruiting vs. Completed (2yr)
Recruiting
624
Completed
371
Competitive Landscape
Sponsor Classification
92%
8%
OTHER (22)
FED (2)
Top Sponsors
SponsorTrialsClass
Children's National Research Institute3OTHER
St. Jude Children's Research Hospital2OTHER
University of Ottawa2OTHER
The Cleveland Clinic2OTHER
Oregon Health and Science University2OTHER
VA Office of Research and Development2FED
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.2OTHER
State University of New York at Buffalo2OTHER
Universitaire Ziekenhuizen KU Leuven1OTHER
Nationwide Children's Hospital1OTHER
Bambino Gesù Hospital and Research Institute1OTHER
Charite University, Berlin, Germany1OTHER
Istituto Auxologico Italiano1OTHER
West China Hospital1OTHER
University of Pennsylvania1OTHER
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
New York7New York
Texas6Houston
Florida6Orlando
Illinois5Chicago
District of Columbia4Washington D.C.
Massachusetts4Boston
Ohio4Cleveland
Pennsylvania4Philadelphia
California4Palo Alto
Maryland4Baltimore
Michigan3Ann Arbor
North Carolina3Durham
Georgia3Atlanta
Minnesota2Minneapolis
Tennessee2Memphis
Mississippi2Jackson
Rhode Island2Providence
Oregon2Portland
Colorado1Aurora
Washington1Seattle
Expansion Intelligence
+31100%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
2
Exact
1
Parent
2
Region
3
Related
3
Comorbid
Top Expansion Terms
  • cerebellar disorder Parent
  • posterior fossa Region
  • cerebellar Region
  • cerebellar mutism Related
  • medulloblastoma Related
  • pediatric brain tumor Related
  • ataxia Comorbid
  • cranial nerve palsy Comorbid
  • behavioral change Comorbid

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for posterior fossa syndrome
high
Standard searches miss 31100% of relevant trials for posterior fossa syndrome — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
622 additional trials found via expansion vs 2 exact matches
high
Phase 2 volume (7) significantly exceeds Phase 3 (3), indicating a pipeline bottleneck — most candidates are 2-4 years from potential approval.
Phase 2/Phase 3 ratio: 2.3x
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for posterior fossa syndrome and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
Changing Tactics? Optimizing ECT in Difficult-to-treat Depression
Universitaire Ziekenhuizen KU Leuven n=196 UPC Kortenberg Kortenberg
Intervention DEVICE: switch to BT electrode position — use of different electrode positions of ECT device
Eligibility Ages 18 Years
Contact Pascal Sienaert, MD,PhD · +322 758 05 11 · pascal.sienaert@upckuleuven.be
NCT05843253 PHASE2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital n=120 Children's Hospital Colorado Aurora, Colorado
Intervention DRUG: Ribociclib — Ribociclib PO qd on days 1-21
Eligibility Ages 12 Months – 39 Years
Contact Kelsey H Troyer, PhD · 16147223284 · kelsey.troyer@nationwidechildrens.org
NCT05298995 PHASE1
GD2-CAR T Cells for Pediatric Brain Tumours
Bambino Gesù Hospital and Research Institute n=54 Ospedale Pediatrico Bambino Gesù Roma, Italy
Intervention BIOLOGICAL: GD2-CART01 (iC9-GD2-CAR T-cells) — Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg ...
Eligibility Ages 6 Months – 30 Years
Contact Francesca Del Bufalo, MD · 00396859 · francesca.delbufalo@opbg.net
Neuroimmunology Registry and Biobank
Charite University, Berlin, Germany n=300 Charité - Universitätsmedizin Berlin Berlin, State of Berlin
Contact Markus Schuelke, MD · +49 30 450 566112 · markus.schuelke@charite.de
Multidimensional Evaluation of Patients' Affected by Obstructive Apnea Syndrome (OSAS) Before and After Ventilotherapy
Istituto Auxologico Italiano n=65 IRCCS Istituto Auxologico Italiano Piancavallo, VCO
Intervention DEVICE: Continuous Positive Airway Pressure Ventilotherapy — Breathing support device during sleeping
Eligibility Ages 20 Years – 60 Years
Contact Sofia Tagini, PhD · 00393339915288 · s.tagini@auxologico.it
Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma
West China Hospital n=450 West China Hospital of Sichuan University Chengdu, Sichuan
Intervention OTHER: Not applicable- observational study — Not applicable- observational study
Eligibility Ages 0 Years – 18 Years
Contact Zhigang Lan, M.D. PhD. · 18980606446 · 158075478@qq.com
UPenn Observational Research Repository on Neurodegenerative Disease
University of Pennsylvania n=1000 University of Pennsylvania Philadelphia, Pennsylvania
Intervention OTHER: No intervention — No intervention
Eligibility Ages 18 Years
Contact Emily Xie · 215-746-2781 · emily.xie@pennmedicine.upenn.edu
NCT05535166 PHASE2
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital n=130 Lucille Packard Children's Hospital Stanford Palo Alto, California
Intervention PROCEDURE: Surgical resection — All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved...
Eligibility Ages 59 Months
Contact Tabatha E. Doyle, RN · 901-595-2544 · tabatha.doyle@stjude.org
Structural Heat Adaptation and Education in Rural Setting
Aga Khan University n=7128 Aga Khan University Hospital Matiari
Intervention BEHAVIORAL: Community education and awareness — This component of the ReHAB will be achieved through community mobilization, which will encompass awareness and motivati...
Contact Jai K Das · +922134864717 · jai.das@aku.edu
Time Restricted Eating for WeIght LoSs MainTenance-2
NYU Langone Health n=110 NYU Langone Health New York, New York
Intervention BEHAVIORAL: TRE — Participants randomized to the TRE arm will be instructed to consume all food and beverages in a self-selected 10-hr eat...
Eligibility Ages 25 Years – 65 Years
Contact Collin Popp · 646-501-3427 · Collin.popp@nyulangone.org
Mississippi Delta Community Care Home Visits Program
Jackson State University n=500 Mississippi State Department of Health Jackson, Mississippi
Intervention BEHAVIORAL: The PEN-3 Intervention Model — The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural p...
Eligibility Ages 18 Years – 45 Years, FEMALE only
Contact Mary Shaw, PhD · 601-979-3103 · mary.shaw@jsums.edu
Accelerated iTBS for Major Depression
Istanbul University - Cerrahpasa n=35 Istanbul University - Cerrahpasa Istanbul
Intervention DEVICE: Accelerated Intermittent Theta Burst Stimulation (iTBS) — Accelerated intermittent theta burst stimulation (iTBS) is administered bilaterally to the dorsomedial prefrontal cortex...
Eligibility Ages 18 Years – 65 Years
Contact Merve Rana Altunel Ülkü, MD · +90 506 303 10 68 · ranaltunel@gmail.com
NCT07017816 EARLY_PHASE1
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
Children's National Research Institute n=18 Children's National Hospital Washington D.C., District of Columbia
Intervention DRUG: SGT-53 — SGT-53 is a novel cationic liposome encapsulating a normal human wild type TP53 cDNA sequence in a plasmid backbone. The...
Eligibility Ages 3 Years – 21 Years
Contact Julia Batarseh · 202-476-5578 · jamore@childrensnational.org
NCT06686121 PHASE3
Improving Mobility After Revascularization in Peripheral Artery Disease
Northwestern University n=386 University of Arizona Tucson, Arizona
Intervention BEHAVIORAL: Home Based Exercise — This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. The...
Eligibility Ages 18 Years
Contact Mary M McDermott, MD · 312-503-6438 · mdm608@northwestern.edu
Using Neuroimaging and Behavioral Assessments to Understand Late Talking
University of Toronto n=45 Grandview Kids Oshawa, Ontario
Intervention BEHAVIORAL: Intervention to address late talking — this intervention is designed to support both speech and language development in children who are toddlers. Given the ag...
Eligibility Ages 18 Months – 30 Months
Contact Karla N Washington, PhD · 416-978-6499 · karla.washington@utoronto.ca
The Impact of Wearing the Hijab on Whole-body Heat Loss During Exercise-heat Stress
University of Ottawa n=12 University of Ottawa Ottawa, Ontario
Intervention OTHER: Exercise-heat stress with no hijab — Participants perform exercise in the heat with no hijab
Eligibility Ages 18 Years – 35 Years, FEMALE only
Contact Glen P Kenny, PhD · 6135625800 · gkenny@uottawa.ca
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
The University of Texas at Dallas n=40 Center for BrainHealth Dallas, Texas
Intervention OTHER: Discontinuation and Reinitiation of Tirzepatide — Participants will temporarily pause their tirzepatide medication for 3-4 weeks and then restart it for 6-8 weeks under t...
Eligibility Ages 18 Years – 70 Years
Contact Samuel H Poelker-Wells, Master of Science · 972-883-3375 · sxp230129@utdallas.edu
tDCS as Treatment for Motor Function
Baycrest n=20 Baycrest Academy of Health Sciences and Geriatric Research Toronto, Ontario
Intervention DEVICE: Transcranial direct current stimulation (TDCS) — The Crossover design will enable us to use each participant as their own control.
Contact Alice Zhang, B.Sc · (416) 785-2500 · azhang4@research.baycrest.org
HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke
Zi-Xiao Li n=70 Beijing Tiantan hospital Beijing
Intervention DEVICE: iTBS group — iTBS on the contralesional cerebellum, twice a day for seven days
Eligibility Ages 18 Years
Contact Weili Jia, Dr. · +86 13120207987 · jiawl1994@163.com
Effects of Cerebellar tACS-iTBS in Ataxia
I.R.C.C.S. Fondazione Santa Lucia n=30 IRCCS Santa Lucia Foundation Rome, Lazio
Intervention DEVICE: Real (real iTBS/tACS + exergaming) — Stimulation will be applied to the cerebellum. The tACS session duration will be 190 seconds with a frequency of 5 Hz co...
Eligibility Ages 8 Years – 80 Years
Contact Giacomo Koch, Prof. · 0651501181 · g.koch@hsantalucia.it